Screening for pre-eclampsia by maternal serum glycosylated fibronectin at 11-13 weeks' gestation.

The variables from maternal characteristics and medical history with significant contribution to the measurement of GlyFn were maternal age, weight, height, race, smoking and previous history of PE. In pregnancies that developed PE, GlyFn MoM was increased and the deviation from normal decreased with increasing gestational age at delivery. The DR and AUC for delivery with PE at <37 weeks' gestation in screening by maternal factors alone were 50% and 0.834, respectively, and these increased to 80% and 0.949, respectively, when maternal risk factors were combined with MAP, UtA-PI and PlGF (triple test). The performance of the triple test was similar to that of screening by a combination of maternal factors with MAP, UtA-PI and GlyFn (DR 79% and AUC 0.946) and in screening by a combination of maternal factors with MAP, PlGF and GlyFn (DR 81% and AUC 0.932). The performance of screening for delivery with PE at ≥37 weeks'gestation was poor with DRs of 35% in screening with maternal factors alone, increasing to only 39% with use of the triple test; Similar results were obtained when GlyFn replaced PlGF or UtA-PI in the triple test. The DRs, at 10% FPR, of GH with delivery at <37 and ≥37 weeks'gestation in screening by maternal factors alone were 34% and 25%, respectively, and these increased to 54% and 31%, respectively in screening by the triple test; similar results were obtained when GlyFn replaced PlGF or UtA-PI in the triple test. This article is protected by copyright. All rights reserved.